Cann Group Limited
Research Cann Group Limited (CAN.AX) on Bullrun: market cap AUD 9.96M, P/E 0.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCAN.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyAUD
- Market capAUD 9.96M
- P/E0.3
- Financial periodFY2026
Valuation Snapshot
latest market cap is AUD 9.96M; P/E is 0.3.
Peer valuation comparison
Latest P/E is 0.3x versus a Healthcare sector median of 21.74x (98.6% below).
Latest P/E is 0.3x versus a Australia median of 14.68x (98.0% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | n/a | n/a | n/a | n/a | 0.02 | n/a | n/a | n/a |
| FY2024 | AUD 15.37M | -AUD 51.24M | -AUD 17.69M | 100.0% | -0.11 | AUD 1.64M | AUD 72.47M | AUD 13.92M |
| FY2023 | AUD 13.78M | -AUD 33.79M | -AUD 25.94M | 100.0% | -0.09 | AUD 765.00K | AUD 60.97M | AUD 59.26M |
| FY2022 | AUD 6.41M | -AUD 26.47M | -AUD 65.60M | 100.0% | -0.07 | AUD 1.91M | AUD 47.17M | AUD 84.90M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-16 | AUD 9.96M | 0.3 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Cann Group Limited
Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe. Its product portfolio includes the Satipharm delivery system for cannabinoids. The company was founded in 2014 and is based in Mildura, Australia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cann Group Limited's market cap?
Cann Group Limited's market capitalization is AUD 9.96M.
What is Cann Group Limited's P/E ratio?
Cann Group Limited's price-to-earnings (P/E) ratio is 0.3.
What does Cann Group Limited do?
Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe. Its product portfolio includes the Satipharm delivery system for cannabinoids. The company was founded in 2014 and is based in Mildura, Australia.